December 16, 2024
Chimeric antigen receptor (CAR)-T cells and T-cell therapies have been used in the treatment of various cancers for several years. In a review published in JAMA, […]
December 16, 2024
SAN DIEGO — The multiple myeloma (MM) drug daratumumab (Darzalex), an anti-CD38 monoclonal antibody, dramatically reduced progression to active MM or death in patients with high-risk […]
December 16, 2024
TOPLINE: Women with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring showed similar quality of life (QOL), anxiety levels, and symptom trajectories compared with […]
December 16, 2024
The phase 3 PADMA trial demonstrated that first-line treatment with palbociclib plus endocrine therapy (ET) significantly improves outcomes compared with standard mono chemotherapy in patients with […]
December 16, 2024
TOPLINE: In patients with stage II or III colorectal cancer (CRC), frequent follow-up testing with CT scans and serum carcinoembryonic antigen (CEA) screening provides no significant […]
December 13, 2024
The European Medicines Agency (EMA) has given a positive recommendation for Rytelo (imetelstat) for the treatment of adult patients with transfusion-dependent anemia due to very low-, […]
December 13, 2024
The European Medicines Agency (EMA) has recommended that a new oral agent, Welireg (belzutifan), be granted conditional marketing authorization for treatment of two different diseases: the […]
December 13, 2024
SAN ANTONIO — For patients with so-called “good-risk” ductal carcinoma in situ (DCIS) who did not have radiation therapy after breast-conserving surgery, adjuvant tamoxifen reduced their […]
December 13, 2024
SAN ANTONIO — Second-line treatment with imlunestrant improved progression-free survival compared with standard endocrine monotherapy in patients with advanced estrogen receptor (ER)–positive, human epidermal growth factor […]